InfuSystem Holdings, Inc.
AMEX:INFUMedical - Instruments & Supplies
+$0.35 today
- Market cap
- $293.89M
- Beta
- 1.42
- P/E (TTM)
- 23.2
- EPS (TTM)
- $0.39
Volume 0.16M
Average 0.16M
INFU Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
InfuSystem Holdings, Inc.AMEX: INFU
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $33.68M fell 3.0% year over year, behind the +3.5% change in trailing-twelve-month revenue. Sequentially, it fell 7.0% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $145.48M (+1.4%) for the fiscal year ending Dec 2026, a slowdown from the +6.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $33.68M-7.0% QoQ
- Last fiscal yearDec 2025
- $143.44M+6.4% YoY
- LTMMar 2026
- $142.4M+3.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3.0% | +1.0% | +3.9 pp |
| 1 year | +6.4% | +1.4% | -4.9 pp |
| 3-year CAGR | +9.3% | +4.1% | -5.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 143.44M USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +8.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 143.44M | +6.4% |
| FY2024 | 2024-12-31 | 134.86M | +7.2% |
| FY2023 | 2023-12-31 | 125.79M | +14.4% |
| FY2022 | 2022-12-31 | 109.91M | +7.4% |
| FY2021 | 2021-12-31 | 102.38M | — |
Revenue vs competitors
How INFU compares with its peers on the latest reported figures
- INFU's LTM Mar 2026 revenue of $142.4M is the 2nd highest of the 3 companies compared; the peer median is $1.1B.
- Its year-over-year change of +3.5% is the 2nd highest of 3, against a peer median of +7.2%.
- Over three fiscal years its annual growth of +9.3% compares with a peer median of +6.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $2.16B | -9.0% | -0.7% | |
| LTM Mar 2026 | $142.4M | +3.5% | +9.3% | |
| LTM Mar 2026 | $43.26M | +23.3% | +13.8% | |
| Peer median (excluding INFU) | $1.1B | +7.2% | +6.5% | |
Competitors are the stored peer set for INFU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 102.38M | 109.91M | 125.79M | 134.86M | 143.44M |
| Cost of Revenue | 43.85M | 49.35M | 62.68M | 64.46M | 63.14M |
| Gross Profit | 58.54M | 60.56M | 63.11M | 70.4M | 80.3M |
| Gross Margin | 57.2% | 55.1% | 50.2% | 52.2% | 56.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 51.45M | 56.41M | 58.03M | 62.52M | 67.46M |
| Operating Expenses | 55.72M | 58.91M | 59.02M | 63.51M | 68.38M |
| Depreciation & Amortization | 14.63M | 13.36M | 12.51M | 12.5M | 13.29M |
| EBITDA | 17.26M | 14.89M | 16.53M | 20.03M | 25.22M |
| EBITDA Margin | 16.9% | 13.5% | 13.1% | 14.9% | 17.6% |
| Operating Income | 2.82M | 1.65M | 4.09M | 6.89M | 11.92M |
| Operating Margin | 2.8% | 1.5% | 3.2% | 5.1% | 8.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.38M | 1.4M | 2.17M | 1.78M | 1.3M |
| Other Income / Expenses | (1.56M) | (1.52M) | (2.24M) | (1.83M) | (1.3M) |
| Income Before Tax | 1.26M | 130K | 1.85M | 5.06M | 10.62M |
| Pre-Tax Margin | 1.2% | 0.1% | 1.5% | 3.8% | 7.4% |
| Income Tax Expense | (163K) | 112K | 979K | 2.71M | 4M |
| Net Income | 1.42M | 18K | 872K | 2.35M | 6.63M |
| Net Margin | 1.4% | 0.0% | 0.7% | 1.7% | 4.6% |
| EPS (Basic) | 0.07 | 0.00 | 0.04 | 0.11 | 0.32 |
| EPS (Diluted) | 0.06 | 0.00 | 0.04 | 0.11 | 0.31 |
| Weighted Avg Shares | 20.52M | 20.65M | 21.02M | 21.27M | 20.66M |
| Weighted Avg Shares (Diluted) | 22.05M | 21.55M | 21.65M | 21.71M | 21.1M |
InfuSystem Holdings, Inc.
AMEX:INFU
Intrinsic Alpha fair value
Locked
Current Price
$14.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.